ImmunityBio, Inc. is listed among the 20 Best Biotech Stocks Under $20 to Buy Now. Piper Sandler raised its price target on IBRX to $7 from $5, predicting U.S. ANKTIVA net sales to reach $180 million in 2026. Positive QUILT-2.005 data in Q4 2026 may support label expansion in 2027.

ImmunityBio, Inc. reported positive Phase 2 QUILT-3.078 results in recurrent GBM, with the longest survival at 12 months and overall survival not yet achieved. 19 out of 23 patients are still living, with a preserved safety profile and improved immunological competence.

ImmunityBio, Inc. is a U.S. biotech company developing immunotherapies and vaccines to combat cancers and infectious diseases. While IBRX shows investment potential, some AI stocks may offer greater upside with less risk. A free report on the best short-term AI stock is available for those interested in undervalued opportunities.

Read more at Yahoo Finance: Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. (IBRX)’s ANKTIVA Following QUILT Data